Clearmind Medicine (CMND) announced the filing of a patent application in South Korea covering compositions containing its proprietary compound, 5-methoxy-2-aminoindane, for the treatment of depression. This filing further strengthens Clearmind’s global intellectual property portfolio for MEAI, a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without the psychoactive effects associated with traditional psychedelics.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces publication of U.S. patent application
- Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Clearmind appoints Mary-Elizabeth Gifford as chief of global impact
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial